Table 3.
Multivariate Cox proportional hazards analyses of AST/ALT ratio on overall survival, cancer-specific survival, and recurrence-free survival after propensity score matching.
| Variables | Overall survival | Cancer-specific survival | Recurrence-free survival | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.03 (1.01-1.04) | <0.001 | 1.02 (0.99-1.03) | 0.092 | 1.00 (0.99-1.02) | 0.876 |
| BMI | 0.92 (0.87-0.96) | <0.001 | 0.94 (0.88-0.99) | 0.034 | 0.97 (0.92-1.02) | 0.299 |
| Tumor size | 1.09 (1.05-1.15) | <0.001 | 1.11 (1.05-1.17) | <0.001 | 1.09 (1.04-1.14) | 0.001 |
| High tumor grade | 1.51 (1.04-2.18) | 0.018 | 1.70 (1.13-2.55) | 0.010 | 1.37 (0.95-1.98) | 0.093 |
| ≥pT2 stage | 5.36 (2.12-13.51) | <0.001 | 6.99 (3.00-16.28) | <0.001 | 13.47 (4.25-42.65) | <0.001 |
| ≥N1 stage | 1.36 (1.05-1.75) | 0.018 | 1.35 (1.05-1.74) | 0.018 | 1.60 (1.25-2.06) | 0.002 |
| ≥M1 stage | 1.27 (0.74-2.18) | 0.394 | 1.71 (0.98-3.00) | 0.060 | 2.10 (1.23-3.60) | 0.007 |
| NACH | 0.51 (0.35-0.75) | 0.001 | 0.45 (0.29-0.69) | <0.001 | 0.47 (0.32-0.67) | <0.001 |
| AST/ALT ratio | ||||||
| AST/ALT ≤1.1 | Reference | Reference | Reference | Reference | Reference | Reference |
| AST/ALT >1.1 | 1.57 (1.20-2.06) | 0.001 | 1.76 (1.26-2.48) | 0.001 | 1.53 (1.15-2.05) | 0.004 |
BMI: body mass index; NACH: neoadjuvant chemotherapy; ALT: alanine aminotransferase; AST: aspartate aminotransferase.